{
    "eid": "2-s2.0-85141939469",
    "title": "Population Pharmacokinetics/Pharmacodynamics and Clinical Outcomes of Meropenem in Critically Ill Patients",
    "cover-date": "2022-11-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Pharmacology",
            "@code": "3004",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology (medical)",
            "@code": "2736",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Infectious Diseases",
            "@code": "2725",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "clinical cure",
        "critically ill",
        "meropenem",
        "population pharmacokinetic",
        "time above MIC"
    ],
    "authors": [
        "Apinya Boonpeng",
        "Sutep Jaruratanasirikul",
        "Monchana Jullangkoon",
        "Maseetoh Samaeng",
        "Thitima Wattanavijitkul",
        "Rungsun Bhurayanontachai",
        "Sutthiporn Pattharachayakul"
    ],
    "citedby-count": 2,
    "ref-count": 37,
    "ref-list": [
        "Recognizing sepsis as a global health priority-a WHO resolution",
        "Incidence and mortality of hospital- and ICU-treated sepsis: results from an updated and expanded systematic review and meta-analysis",
        "Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock",
        "Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program",
        "Meropenem clinical pharmacokinetics",
        "Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men",
        "Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'",
        "Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia",
        "Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T.MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections",
        "Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration?. Monte Carlo dosing simulations and subcutaneous tissue distribution",
        "Optimization of meropenem dosage in the critically ill population based on renal function",
        "Population pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care units",
        "A nonparametric pharmacokinetic approach to determine the optimal dosing regimen for 30-minute and 3-hour meropenem infusions in critically ill patients",
        "Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients",
        "Optimising meropenem dosing in critically ill Australian Indigenous patients with severe sepsis",
        "Development of a dosing nomogram for continuous-infusion meropenem in critically ill patients based on a validated population pharmacokinetic model",
        "Population pharmacokinetics analysis and dosing simulations of meropenem in critically ill patients with pulmonary infection",
        "Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic/pharmacodynamic analysis",
        "Meropenem target attainment and population pharmacokinetics in critically ill septic patients with preserved or increased renal function",
        "Population pharmacokinetics of standarddose meropenem in critically ill patients on continuous renal replacement therapy: a prospective observational trial",
        "Dosing regimen of meropenem for adults with severe burns: a population pharmacokinetic study with Monte Carlo simulations",
        "The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients",
        "Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Soci\u00e9t\u00e9 Fran\u00e7aise de Pharmacologie et Th\u00e9rapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Soci\u00e9t\u00e9 Fran\u00e7aise d'Anesth\u00e9sie et R\u00e9animation-SFAR)",
        "Pharmacokinetics and pharmacodynamics ofmeropenemin elderly Chinese with lower respiratory tract infections: population pharmacokinetics analysis using nonlinear mixed-effects modelling and clinical pharmacodynamics study",
        "Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection",
        "Effect of obesity on the population pharmacokinetics of meropenem in critically ill patients",
        "Population pharmacokinetics of meropenem in elderly patients: dosing simulations based on renal function",
        "Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial",
        "Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study",
        "Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia",
        "Meropenem penetration into epithelial lining fluid in mice and humans and delineation of exposure targets",
        "A rapid, sensitive high performance liquid chromatographic method for the determination of meropenem in pharmaceutical dosage form, human serum and urine",
        "Dosing of medications in morbidly obese patients in the intensive care unit setting",
        "Quantification of lean bodyweight",
        "Estimation of creatinine clearance in patients with unstable renal function, without a urine specimen",
        "The third international consensus definitions for sepsis and septic shock (sepsis-3)"
    ],
    "affiliation": [
        {
            "affiliation-city": "Phayao",
            "@id": "60114221",
            "affilname": "University of Phayao",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60114221",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Hatyai",
            "@id": "60025527",
            "affilname": "Faculty of Medicine, Prince of Songkia University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60025527",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Hatyai",
            "@id": "60006314",
            "affilname": "Prince of Songkla University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60006314",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Faculty of Medicine, Faculty of Pharmaceutical Sciences",
        "Prince of Songkla University, Thailand and Doctor Kasem Pangsrivongse Foundation"
    ]
}